The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Research and development of naltrexone: a new narcotic antagonist

Published Online:https://doi.org/10.1176/ajp.136.6.782

The author reviews the history of federally supported research in the field of narcotic antagonist therapy, focusing on social, political, and governmental issues. He describes the criteria for establishing an optimum narcotic antagonist, the legal guidelines for drug development, and the currently available narcotic antagonists. Research supported by the National Institute on Drug Abuse has indicated that naltrexone is the most promising drug in this category. The author discusses the safety and clinic use of naltrexone, the status of the NIDA naltrexone program, and plans for future development of the drug.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.